Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy
Shouheng Lin(Chinese Academy of Sciences), Peng Li(Chinese Academy of Sciences), Baiheng Li(Chinese Academy of Sciences), Duanqing Pei(Westlake University), Shuzhong Cui(Guangzhou Medical University), Qiuhua Deng(Nanfang Hospital), Suna Wang(Liaocheng University), Qiting Wu(Chinese Academy of Sciences), Zhesheng Wen(Sun Yat-sen University), Wei Wei(Institute of Process Engineering), Zhen Li(Tongji Hospital), Yao Yao(Dalian Medical University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Yang Li(Shanghai First People's Hospital), Zhenfeng Zhang(Dalian Medical University), Xiaofang Sun(Third Affiliated Hospital of Guangzhou Medical University), Simiao Lin(Chinese Academy of Sciences), Yiren Xiao(Chinese Academy of Sciences), Lin Cheng(Chinese Academy of Sciences), Guohua Huang(Nanfang Hospital), Huihui Yao(Soochow University), Yuchuan Jiang(Sun Yat-sen University), Xueming Qian(Bioscience (China)), Su Mei Cao, Xuchao Zhang(Guangdong General Hospital), Pentao Liu(Hong Kong Science and Technology Parks Corporation)
Cited by 88
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k